arrow_back
Medical Information
  • GILEAD and the GILEAD logo are trademarks of Gilead Sciences, Inc. KITE and the KITE logo are trademarks of Kite Pharma, Inc. © 2024 Gilead Sciences, Inc. All rights reserved. IHQ-UNB-5659 May 2024

Breast research.

There is a 1 in 8 chance a woman develops breast cancer in her lifetime. In the U.S. alone, it is estimated ~298,000 women will be diagnosed with breast cancer each year. Breast cancer can be broken up into several subtypes based on the presence of hormone or HER2 receptors. Treatment for patients with breast cancer varies based on the specific subtype the patient is diagnosed with.1,2

Research commitment
Clinical trials in progress
Scientific focus

Committed to patients living with breast cancer

Select a trial below to view additional details (trial brochure or clinicaltrials.gov)
Timeline is based on trial start dates.
The safety and efficacy of these investigational agents or investigational uses of marketed products have not been established. These uses have not been approved by regulatory authorities. There is no guarantee that these therapies or uses will be commercialized.

2012
IMMU-132-001a

Adv epithelial cancers

2017
ASCENTa

2L+ mTNBC

2019
TROPiCS-02a

HR+/HER2- mBC

2020
EVER-132-001b,*

2L+ mTNBC

 
EVER-132-002b,*

2L+ HR+/HER2- mBC

2021
ASCENT-J02*

2L+ mTNBC

2022
ASCENT-03*

1L mTNBC, PD-L1-

 
ASCENT-04*

1L mTNBC, PD-L1+

 
ASCENT-05d,*

Adjuvant mTNBC

2023
ASCENT-07

HR+/HER2- chemo-naïve mBC

00

Clinical trials in progress

Breast clinical trials actively recruiting.

Rollover trial for links to trial brochures and/or clinicaltrials.gov records.

The safety and efficacy of these investigational agents or investigational uses of marketed products have not been established. These uses have not been approved by regulatory authorities. There is no guarantee that these therapies or uses will be commercialized.

1L mTNBC, PD-L1–
Phase 3 randomized, open-label study of sacituzumab govitecan versus treatment of physician’s choice in patients with previously untreated, locally advanced, inoperable, or mTNBC whose tumors do not express PD-L1 or in patients previously treated with anti-PD(L)1 agents in the early setting whose tumors do express PD-L1
TNBC

ASCENT-03

1L mTNBC, PD-L1+
Phase 3 randomized, open-label study of sacituzumab govitecan and pembrolizumab versus treatment of physician’s choice and pembrolizumab in patients with previously untreated, locally advanced inoperable or mTNBC whose tumors express PD-L1
TNBC

ASCENT-04a

Adjuvant TNBC
Phase 3 randomized, open-label study of adjuvant sacituzumab govitecan and pembrolizumab versus treatment of physician’s choice in patients with TNBC who have residual invasive disease after surgery and neoadjuvant therapy
TNBC

ASCENT-05b

HR+/HER2- chemo-naïve mBC
Phase 3 randomized, open-label study of sacituzumab govitecan versus treatment of physician’s choice in patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2 negative (HER2–) (HER2 IHC0 or HER2-low [IHC 1+, IHC2+/ISH-]) inoperable, locally advanced, or metastatic breast cancer and have received endocrine therapy
HR+/HER2- mBC

ASCENT-07

Scientific focus

The safety and efficacy of these investigational agents or investigational uses of marketed products have not been established. These uses have not been approved by regulatory authorities. There is no guarantee that these therapies or uses will be commercialized.

MoAs in research

sacituzumab govitecan-hziy

Clinicaltrials.gov may not reflect the most up-to-date information on the trials shown.

*Ongoing trials

aTrial status: active, not recruiting. bIn collaboration with Merck. cIn collaboration with Alliance Foundation Trials, LLC. and the National Surgical Adjuvant Breast and Bowel Project Foundation, Inc

BC, breast cancer; HR, hormone receptor; HER2, human epidermal growth factor receptor; m, metastatic; NCT, national clinical trial; PD-L1, programd death-lignd 1; TNBC, triple-negative breast cancer.

1. Sung H, et al. CA Cancer J Clin. 2021;71(3):209-249 2. National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) Cancer Stat Facts: Female Breast Cancer Subtypes — Cancer Stat Facts. Available at https://seer.cancer.gov/statfacts/html/breast-subtypes.html. Accessed May 30, 2023.